Emily J. Hanan
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Cancer-related Molecular Pathways, Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα(2022)125 cited
- → Discovery of a potent and selective Aurora kinase inhibitor(2008)108 cited
- → Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye(2012)96 cited
- → Structure of the essential inner membrane lipopolysaccharide–PbgA complex(2020)96 cited
- → Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors(2012)89 cited
- → Monomeric Targeted Protein Degraders(2020)62 cited
- → Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2(2012)61 cited
- → Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation(2014)61 cited
- → Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study(2015)56 cited
- → Mild and General One-Pot Reduction and Cyclization of Aromatic and Heteroaromatic 2-Nitroamines to Bicyclic 2H-Imidazoles(2010)53 cited